Paris, France: Sanofi announced today that iGlarLixi, the investigational, titratable fixed-ratio combination of insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide*, offers greater control of mealtime blood sugar (post-prandial glucose, PPG) in adults living with type 2 diabetes compared to insulin glargine 100 Units/mL alone. A new post-hoc analysis of data from the LixiLan-L pivotal Phase III clinical trial found more patients who received the fixed-ratio combination reached their daily PPG target than those who received only insulin glargine 100 Units/mL. The new analysis was presented at the European Association for the Study of Diabetes (EASD) 52nd Annual Meeting in Munich, Germany. iGlarLixi is currently under review in the United States and Europe.
“Controlling mealtime blood sugar is an important element of maintaining overall blood sugar control, which plays a role in helping patients treat their diabetes,” said Josep Vidal, Hospital Clinic of Barcelona, Barcelona, Spain, and lead author of the study. “This new analysis provides further evidence supporting the use of iGlarLixi by adults with type 2 diabetes who need mealtime blood sugar control alongside greater control of their HbA1c.”
The analysis also showed that a significantly higher proportion of participants reached their PPG target after 30 weeks, according to self-measured plasma glucose (SMPG) taken at intervals throughout the day. As previously reported for LixiLan-L, incidence of symptomatic hypoglycemia was similar with the titratable fixed-ratio combination and insulin glargine 100 Units/mL.
“In the LixiLan-L pivotal Phase III clinical trial, investigational iGlarLixi demonstrated superior HbA1c reduction compared with insulin glargine 100 Units/mL alone,” said Riccardo Perfetti, Head of Global Diabetes Medical Team, Sanofi. “With this new analysis, we see further evidence of the role iGlarLixi can serve in helping type 2 diabetes patients meet their PPG targets.”
The presentation abstract is titled ‘Post-Prandial Glycemic Outcomes of a Fixed Ratio Combination of Insulin Glargine and Lixisenatide in the LixiLan-L Trial (NCT02058147)’ (Vidal, J et al. Poster presentation 801 – EASD 52nd Annual Meeting in Munich, Germany at 13:15 p.m. CET on September 13)
Summary of Results
The post-hoc analysis reviewed data from the LixiLan-L pivotal Phase III trial, which compared the effectiveness of the two treatments in 736 adults whose type 2 diabetes was not adequately controlled at screening on insulin glargine alone or combined with one or two oral anti-diabetic agents. The primary outcome of the LixiLan-L study, a statistically significant reduction in HbA1c (average blood glucose over the previous three months) compared with insulin glargine 100
Units/mL, was previously reported at the American Diabetes Association 76th Scientific Sessions,
In the 677 participants included in the post-hoc analysis with standardized meal test data at baseline and week 30, the fixed-ratio combination demonstrated greater PPG control compared with insulin glargine 100 Units/mL. The percentage of patients achieving PPG ≤7.8 mmol/L at Week
30 was greater in the fixed-ratio combination group versus the insulin glargine 100 Units/mL group at 0.5 hour (difference: 16.4% [41.4% vs. 25%], p<0.0001); one hour (difference: 22.4% [30.7% vs.
8.3%], p<0.0001) and two hour (difference: 28.2% [33.6% vs. 5.4%], p<0.0001) after a standardized
liquid meal.The fixed-ratio combination also demonstrated greater PPG control compared with insulin glargine
100 Units/mL in the 592 participants included in the post-hoc analysis with 7-point self-measured plasma glucose (SMPG) data at baseline and week 30. Consistently, more patients reached PPG
targets after all meals throughout the day. The percentage of patients achieving PPG ≤7.8 mmol/L
in a 7-point SMPG test at Week 30 was greater in the fixed-ratio combination group versus the insulin glargine 100 Units/mL group at 10 a.m. (difference: 32.5% [61.2% vs. 28.7%], p<0.0001); 3
p.m. (difference: 16.5% [41.1% vs. 24.6%], p<0.0001) and 10 p.m. (difference: 12.2% [45.9% vs.
33.7%], p=0.005).As previously reported for LixiLan-L, documented (≤70 mg/dL /3.9 mmol/L) incidence of symptomatic hypoglycemia was similar with the titratable fixed-ratio combination (40% of patients;
3.0 events/year; E/Y) and insulin glargine 100 Units/mL (42.5% of patients; 4.2 E/Y). With the titratable fixed-ratio combination, 10.4% of participants experienced nausea, and 3.6% experienced
vomiting; while with insulin glargine 100 Units/mL 0.5% of participants experienced nausea and
0.5% experienced vomiting.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Copyright © 2014 - 2021 The Global Indian New Network (TGINN)
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.